Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
2
×
Tags
biotech
boston
2
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
allergan
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
crispr
cynthia collins
drugs
duchenne muscular dystrophy
dyne therapeutics
editas medicine
facioscapulohumeral muscular dystrophy
gene editing
gene therapy
joshua brumm
kaleido biosciences
katrine bosley
leber congenital amaurosis
muscular dystrophy
myotonic dystrophy type 1
national top stories
new york blog main
rare disease drugs
romesh subramanian
san diego blog main
san francisco blog main
susanna high
vertex pharmaceuticals
What
experimental
2
×
humans
2
×
ago
allergan
biotechs
blessing
bosley
ceo
check
clinical
considering
crispr
cusp
data
depart
diseases
drug
dyne
early
editas
editing
expected
eyes
gene
genetic
having
ipo
ipos
katrine
long
medicine
medicines
million
muscle
partner
rare
reach
regulatory
test
therapeutics
Language
unset
Current search:
experimental
×
humans
×
boston
×
photo
×
@xconomy.com
4 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial